UP!

BDX $224.08   View long term graphs

Becton, Dickinson and Company
Type
Public
Traded as NYSE: BDX
S&P 500 Component
Industry Medical equipment
Founded East Rutherford, New Jersey (1897 (1897))
Founder Maxwell Becton and Fairleigh S. Dickinson
Headquarters BD Headquarters
Franklin Lakes, New Jersey
, U.S.
Area served
Worldwide
Key people

Vincent Forlenza (Chairman), CEO
Tom Polen (President)
Chris Reidy (Acting Chief Financial Officer, Senior Vice President and Controller)

William A. Kozy (SVP and COO)
Revenue DecreaseUS$10.28 billion (FY 2015)
Operating income
DecreaseUS$1.07 billion (FY 2015)
Net income
DecreaseUS$695 million (FY 2015)
Total assets IncreaseUS$26.8 billion (FY 2015)
Total equity IncreaseUS$7.16 billion (FY 2015)
Number of employees
Increase49,500 (September 2015)
Divisions BD Medical; BD Life Sciences
Website bd.com

Vincent Forlenza (Chairman), CEO
Tom Polen (President)
Chris Reidy (Acting Chief Financial Officer, Senior Vice President and Controller)

Coordinates: 41°00′57″N 74°12′36″W / 41.015834°N 74.210136°W / 41.015834; -74.210136

Becton, Dickinson and Company (BD) is an American medical technology company that manufactures and sells medical devices, instrument systems, and reagents. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 50,000 people in more than 50 countries throughout the world. In fiscal year ending September 30, 2009, 60% of BD sales were generated from non-U.S. markets.

The company's customers include healthcare institutions, science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD was one of the first companies to sell U.S.-made glass syringes. It was also a pioneer in the production of hypodermic needles. Today, BD is divided into two segments: BD Medical and BD Life Sciences. BD is ranked #225 in the 2017 Fortune 500 list.

The firm in October 2014 agreed to acquire CareFusion for a price of $12.2 billion in cash and stock. In April 2017 Becton Dickinson agreed to acquire C. R. Bard for $24 billion.

BD was founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson, two American businessmen who met on a sales trip. The same year the company made its first sale, a Luer-all-glass syringe that sold for $2.50. In 1898, BD acquired its first patent for a medical product. In 1899 the company introduced its first logo which was meant to symbolize guaranteed superior quality of the products provided by BD. In 1904, BD acquired the Philadelphia Surgical Company. This very first acquisition and other early acquisitions significantly expanded the company’s manufacturing ability and product offering. Two years later, BD incorporated in the State of New Jersey and built a manufacturing facility in East Rutherford, the first in the U.S. created specifically for the production of thermometers, hypodermic needles, and syringes. In 1924, BD manufactured its first syringe designed specifically for insulin injection. One year later, BD introduced the BD Yale Luer-Lok Syringe, designed and patented by Fairleigh S. Dickinson, Sr. It provided a simple and secure method of attaching and removing the needle to and from the syringe. Today, luer lock connectors are the standard for syringes in the U.S. In 1947 Joseph Kleiner developed the Evacutainer—a device used to draw blood by vacuum through a needle into a test tube. This product eventually evolved to become the BD Vacutainer Blood Collection system.

In 1948, BD faced new leadership as Fairleigh S. Dickinson, Jr. and Henry P. Becton, sons of the founders, took over the company. Their 24-year tenure was a time of rapid development for BD. The company grew within the U.S. as well as internationally. In 1949, it opened its first manufacturing site outside of New Jersey in Columbus, Nebraska. In 1961, it established a manufacturing facility in Canaan, Connecticut. BD also soon expanded to Canada (1951), Mexico (1952), France (1955), and Brazil (1956). The tenure of Fairleigh S. Dickinson, Jr. and Henry P. Becton was also a time of significant product innovation. In 1950, BD's first sterile disposable product, a blood collection set, was developed and sold to the American Red Cross. In 1954, BD introduced the first completely disposable syringe made of glass: BD Hypak. This innovative product was used in a large-scale field test of the polio vaccine developed by Dr. Jonas Salk. One year later, BD entered the microbiology field through the acquisition of the Baltimore Biological Laboratory. In 1961, the company introduced its disposable BD Plastipak syringe. Under the new leadership the company also went public (1962) and appeared for the first time in the Fortune 500 list (1970).

In 1973, BD added another U.S. facility—a research center in Durham, North Carolina in Research Triangle Park. The center was established to help the company meet United States Environmental Protection Agency (EPA) requirements, research improved manufacturing and process methods, and develop future innovative technologies. In 1975, BD Pharmaceutical Systems Europe acquired an important patent for a prefilled syringe injecting heparin. In 1980, BD developed its first automated system for mycobacteria testing—the BD BACTEC 460TB System. The next year brought significant signs of the company’s development as sales surpassed the $1 billion milestone and a new plant in Plymouth, England was constructed to serve the European markets. Five years later BD moved its corporate headquarters to Franklin Lakes, New Jersey (current HQ location.) Also in 1986, BD acquired Fabersanitas Industrial, a major Spanish syringe manufacturer as well as Deseret Medical, a vascular access devices manufacturer. The last three years of the 1980s also showed growth in Asia (manufacturing facilities in Singapore and Japan.) Furthermore, BD became the first company to introduce a safety-engineered syringe—BD Safety-Lok (1988) and acquired the Beaver Blade Company, a manufacturer of high-quality surgical blades. The first half of the next decade was very important to BD’s development. The company opened a central distribution center in Temse, Belgium (1992) and entered India and China (1995.) BD also introduced a device that offered needle stick protection following blood-drawing procedures—BD Vacutainer Safety-Lok Blood Collection Set.

In 1999, as BD passed more than 100 years of presence in the medical devices industry, BD announced its new corporate identity. Numerous independent brand names were replaced by a single name: BD. In addition, the company symbol that is used today was introduced. BD also named Edward J. Ludwig as the company’s president. Ludwig was also named Chief Executive Officer (2000) and Chairman of the Board of Directors (2002). On February 9, 1999, BD announced the acquisition of Biometric Imaging, Inc. (BMI), a privately held company serving the transfusion medicine, infectious diseases, and oncology markets. On December 20, 2000, BD signed an agreement to acquire Gentest Corporation, a privately held company serving the life sciences market in the areas of drug metabolism and toxicology testing of pharmaceutical candidates. During that time, BD also got heavily involved in global health issues announcing a five-year maternal and neonatal tetanus worldwide elimination partnership with UNICEF (1999), launching the BD Safety Compliance Initiative (2000), and pledging $1 million contribution to the International AIDS Vaccine Initiative (2002.) In 2003 and 2004, BD introduced several innovative products: BD FACSAria Cell Sorter—the first entirely new instrument in the next-generation portfolio of flow cytometers (2003), BD Accuspray—a nasal drug delivery system for administering vaccines (2003), BD.id—a patient identification system designed to limit the potential for medical errors in specimen collection (2003), and the world's first "intelligent" insulin pump and glucose monitoring system, a wireless system consisting of a Medtronic MiniMed Paradigm 512 Insulin Pump and Paradigm Link Blood Glucose Monitor, co-developed with BD. In the beginning of the 21st century BD also invested in growing its business by acquiring several strategically important companies. In 2001, it acquired the Gentest Corporation, a leading in drug metabolism and toxicology testing company. In 2004, BD completed the acquisition of Atto Bioscience Acquired, a company specializing in optical instrumentation, software, and reagents for real-time analysis of interactions taking place in living cells. In 2005 BD entered the field of proteomics through its acquisition of FFE Weber GmbH, which specialized in the separation and fractionation of complex proteins. 2006 was also an important year to document BD's growth as the company acquired GeneOhm Sciences—a leader in the development of molecular diagnostic testing for the rapid detection of bacterial organisms and TriPath Imaging—a cancer diagnostics company.

Becton Dickinson is divided into two business segments: BD Medical (52% of FY 09 revenues) and BD Life Sciences (44% of FY 09 revenues)

The BD Medical segment consists of three divisions or units: Medical & Procedural Solutions, Pharmaceutical Systems, and Diabetes Care. The products of this segment include: needles and syringes, intravenous catheters, safety-engineered and auto-disable devices, prefillable drug delivery systems, prefilled IV flush syringes, insulin syringes and pen needles, regional anesthesia needles, and trays. This segment primarily sells to: hospitals and clinics, physicians' office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, and healthcare workers.

BD Life Sciences consist of three divisions or units: Preanalytical Systems, Diagnostic Systems, and Biosciences. BD Life Sciences specializes in the design, production, and sales of the following products: integrated systems for specimen collection, safety-engineered blood collection products and systems, automated blood culturing systems, molecular testing systems for sexually transmitted diseases and HAIs, microorganism identification and drug susceptibility systems, liquid-based cytology systems for cervical cancer screening, rapid diagnostic assays, and plated media. Customers of this division include: hospitals, laboratories and clinics, reference laboratories, blood banks, healthcare workers, public health agencies, physicians’ office practices, and industrial and food microbiology laboratories.

BD Biosciences designs, manufactures, and sells fluorescence-activated cell sorters and analyzers, monoclonal antibodies, and kits for cell analysis, reagent systems for life science research, cell imaging systems, laboratory products for tissue culture and fluid handling, and cell culture media supplements for biopharmaceutical manufacturing. BD Biosciences serves the following customers: research and clinical laboratories, academic and government institutions, pharmaceutical and biotechnology companies, hospitals, and blood banks. The company's line of plastic conical screwtop test tubes, known as 'Falcon tubes', is popular and the term is sometimes used as a generic term for such tubes.

As a large global company in the healthcare industry, BD has the potential to affect the health and life of many people around the world.

BD has actively donated cash, product, and expertise to non-profit and educational organizations worldwide. In recent years, it formed philanthropic and charitable partnerships with the following organizations: UNICEF, American Red Cross, U.S. President’s Emergency Plan for AIDS Relief, Stop TB Partnership, Global Business Coalition on Health (GBCHealth), Americares, International AIDS Vaccine Initiative, Foundation for Innovative New Diagnostics, Juvenile Diabetes Research Foundation, Project Hope, Direct Relief International, Accordia Global Health Foundation, Columbia University, and University of Virginia. BD has also donated millions to Fairleigh Dickinson University (of which BD co-founder Dickinson was a benefactor and namesake), in support of the Henry P. Becton School of Nursing and Allied Health (named for the son of BD's co-founder, also a BD executive), along with other FDU programs.

As of February 2010, BD was ranked 18th in the EPA Fortune 500 List of Green Power Purchasers. BD was also listed among the top 100 companies in Newsweek’s 2009 Green Rankings ranking of the 500 largest American corporations based on environmental performance, policies, and reputation. BD placed third in the Healthcare sector and 83rd overall. In addition, BD has been a component of the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the four and five consecutive years, respectively.

In mid-2007, the firm's Discardit II series of syringes numbered 0607186 was withdrawn from hospitals and other medical services around Poland, about half a year after the discovery of remains of dark dust in some syringes which were alleged to have been from this series. The newspaper Dziennik Online claimed that other series such as 06022444, 0603266, and 0607297 were also suspected of being contaminated. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. Legal proceedings related to the incident started in December 2006. According to an article published in Dziennik on Monday, 21 April 2008, the prosecutor’s office in Lublin discontinued the inquiry because the disposable syringes were not dangerous.

In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the cause of the problem was manufacturing deviation and claimed that it corrected the problem. BD announced that it notified customers about the recall by letter and has been working with the U.S. Food and Drug Administration and worldwide health agencies to coordinate recall activities.

In April 2016, the Occupational Safety and Health and Administration fined BD $112,700 for safety violations. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2021 2021-02-04 Future report Set alerts
Q4 2020 2020-11-03 Future report Set alerts
Q3 2020 2020-08-06 2.20 0.97
Q2 2020 2020-05-07 2.55 0.53
Q1 2020 2020-02-06 2.65 0.87
Q4 2019 2019-11-05 3.31 0.45
Q3 2019 2019-08-06 3.08 1.51
Q2 2019 2019-05-09 2.59 -0.07
Q1 2019 2019-02-05 2.70 2.05
Q4 2018 2018-11-06 2.93 -0.64

Ratings

2016-06-12 Reiterated Rating Argus Buy
2016-06-01 Downgrade Evercore ISI Buy to Hold
2016-05-18 Reiterated Rating Leerink Swann Hold $175.00
2016-05-12 Reiterated Rating Bank of America Buy
2016-05-12 Reiterated Rating Bank of America Corp. Buy
2016-05-09 Boost Price Target RBC Capital Sector Perform $153.00 to $169.00
2016-05-09 Boost Price Target Royal Bank Of Canada Sector Perform $153.00 to $169.00
2016-05-08 Reiterated Rating Leerink Swann Hold
2016-05-08 Reiterated Rating Morgan Stanley Hold
2016-05-07 Reiterated Rating Evercore ISI Hold $154.00 to $165.00
2016-05-03 Reiterated Rating JPMorgan Chase & Co. Buy
2016-04-08 Boost Price Target Goldman Sachs $156.00 to $157.00
2016-04-08 Boost Price Target Goldman Sachs Group Inc. $156.00 to $157.00
2016-03-16 Reiterated Rating Jefferies Group Buy $175.00
2016-03-10 Reiterated Rating Jefferies Group Buy $175.00
2016-02-11 Upgrade Deutsche Bank Hold to Buy $155.00 to $163.00
2016-02-11 Upgrade Deutsche Bank AG Hold to Buy $155.00 to $163.00
2016-02-04 Lower Price Target Leerink Swann Market Perform $157.00
2016-02-04 Lower Price Target Goldman Sachs Neutral $155.00 to $152.00
2016-02-04 Lower Price Target Citigroup Inc. Neutral $153.00 to $146.00
2016-02-04 Lower Price Target RBC Capital Sector Perform $162.00 to $153.00
2016-01-07 Boost Price Target Cowen and Company $180.00
2016-01-07 Reiterated Rating Argus Buy $167.00
2016-01-06 Downgrade Evercore ISI Buy to Hold $160.00
2016-01-04 Downgrade Morgan Stanley Overweight to Equal Weight $170.00
2015-12-11 Boost Price Target Raymond James Strong-Buy $172.00 to $176.00
2015-12-11 Boost Price Target Raymond James Financial Inc. Strong-Buy $172.00 to $176.00
2015-11-22 Reiterated Rating Piper Jaffray Overweight $160.00 to $171.00
2015-11-22 Reiterated Rating Piper Jaffray Cos. Overweight $160.00 to $171.00
2015-11-19 Reiterated Rating William Blair Outperform
2015-11-12 Initiated Coverage Citigroup Inc. Neutral $153.00
2015-08-19 Reiterated Rating Argus Buy $167.00
2015-08-10 Boost Price Target Deutsche Bank Hold $147.00 to $155.00
2015-08-10 Reiterated Rating JPMorgan Chase & Co. Buy $175.00
2015-08-07 Boost Price Target Leerink Swann Market Perform $157.00 to $162.00
2015-08-07 Reiterated Rating RBC Capital Sector Perform $150.00 to $162.00
2015-07-02 Reiterated Rating Barclays Equal Weight $158.00 to $158.00
2015-07-02 Reiterated Rating Barclays PLC Equal Weight $158.00 to $158.00
2015-05-28 Reiterated Rating Evercore ISI Buy $158.50
2015-05-07 Set Price Target Canaccord Genuity Hold $145.00
2015-03-27 Reiterated Rating Leerink Swann Market Perform $150.00 to $158.00
2015-03-24 Boost Price Target Canaccord Genuity Hold $125.00 to $149.00
2015-03-24 Reiterated Rating Goldman Sachs Neutral $158.00
2015-02-11 Boost Price Target Argus Buy $140.00 to $156.00
2015-02-06 Reiterated Rating Deutsche Bank Hold $145.00 to $147.00
2015-02-06 Boost Price Target RBC Capital Buy $145.00 to $150.00
2015-01-21 Upgrade Cowen and Company Market Perform to Outperform
2015-01-09 Downgrade SunTrust Buy to Neutral
2015-01-09 Downgrade SunTrust Banks Inc. Buy to Neutral
2015-01-06 Upgrade Bank of America Neutral to Buy $147.00 to $163.00
2015-01-05 Upgrade Raymond James Market Perform to Strong-Buy $165.00
2014-12-17 Boost Price Target Piper Jaffray Overweight $141.00 to $160.00
2014-11-26 Reiterated Rating Deutsche Bank Hold $141.00 to $145.00
2014-11-26 Upgrade JPMorgan Chase & Co. Neutral to Overweight $134.00 to $160.00
2014-11-25 Reiterated Rating Evercore ISI Buy $130.00
2014-11-05 Reiterated Rating Bank of America Neutral $132.00 to $135.00
2014-10-14 Reiterated Rating Bank of America Neutral $124.00 to $132.00
2014-10-08 Boost Price Target RBC Capital Sector Perform $116.00 to $132.00
2014-10-07 Upgrade Stifel Hold to Buy $153
2014-10-07 Boost Price Target Canaccord Genuity Hold $113.00 to $125.00
2014-10-07 Boost Price Target Argus Buy $125.00 to $140.00
2014-10-07 Upgrade Stifel Nicolaus Hold to Buy $153.00
2014-10-06 Upgrade JPMorgan Chase & Co. Underweight to Neutral $115.00
2014-08-01 Reiterated Rating JPMorgan Chase & Co. Underweight $111.00 to $115.00
2014-08-01 Boost Price Target RBC Capital $113.00 to $116.00
2014-08-01 Boost Price Target Leerink Swann $117.00 to $120.00
2014-08-01 Boost Price Target Deutsche Bank $119.00 to $123.00
2014-08-01 Boost Price Target Barclays Underweight $115.00 to $121.00
2014-08-01 Reiterated Rating Morgan Stanley Hold $119.00 to $123.00
2014-08-01 Boost Price Target Canaccord Genuity $110.00 to $113.00
2014-07-09 Boost Price Target Evercore ISI Buy $126.50 to $127.50
2014-06-30 Boost Price Target Barclays Underweight $112.00 to $115.00
2014-06-09 Boost Price Target SunTrust Buy $128.00 to $138.00
2014-05-09 Boost Price Target RBC Capital Sector Perform $109.00 to $113.00
2014-05-02 Boost Price Target Canaccord Genuity $108.00 to $110.00
2014-04-07 Reiterated ISI Group Buy $123 to $130
2014-04-07 Boost Price Target Evercore ISI Buy $123.00 to $130.00
2014-02-05 Upgrade Raymond James Underperform to Market Perform
2014-02-05 Boost Price Target Leerink Swann $107.00 to $113.00
2014-01-21 Upgrade Piper Jaffray Overweight $18.00
2014-01-09 Boost Price Target Barclays Underweight $106.00 to $112.00
2014-01-07 Upgrade Bank of America Underperform to Neutral $117.00 to $95.00
2013-11-17 Reiterated Rating Jefferies Group Buy $120.00
2013-11-12 Boost Price Target Argus Buy $115.00 to $125.00
2013-11-06 Boost Price Target RBC Capital Sector Perform $103.00 to $108.00
2013-11-06 Boost Price Target Jefferies Group Buy $116.00 to $120.00
2013-11-06 Boost Price Target Canaccord Genuity Hold $100.00 to $108.00
2013-11-05 Boost Price Target Cowen and Company Buy $111.00 to $117.00
2013-10-11 Initiated Coverage SunTrust Buy
2013-09-18 Upgrade Piper Jaffray Neutral to Overweight $91.00 to $117.00
2013-06-25 Initiated ISI Group Buy $106.50
2013-06-17 Reiterated Argus Buy $95 to $115
2013-05-03 Reiterated Mizuho Neutral $87 to $96
2013-02-14 Reiterated Argus Buy $87 to $95
2013-01-22 Downgrade Mizuho Buy to Neutral $87
2012-09-24 Downgrade Barclays Equal Weight to Underweight $76 to $82
2011-06-21 Reiterated Argus Buy $90 to $96
2011-01-25 Reiterated Barclays Capital Equal Weight $78 to $85
2016-06-12 Reiterated Rating Argus Buy
2016-06-01 Downgrade Evercore ISI Buy to Hold
2016-05-18 Reiterated Rating Leerink Swann Hold $175.00
2016-05-12 Reiterated Rating Bank of America Buy
2016-05-12 Reiterated Rating Bank of America Corp. Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
FORLENZA VINCENT A Chairman, CEO and President 0.11%  (208883) BDX / MCO /
BECTON HENRY P JR 0.06%  (112683) BDX /
COHEN GARY M Executive Vice President 0.04%  (71770) BDX / PRGO /
KOZY WILLIAM A Executive Vice President 0.04%  (68823) BDX / COO /
Groetelaars John P EVP 0.02%  (42508) BCR / BDX /
Khichi Samrat S. EVP and General Counsel 0.02%  (31385) BCR / BDX /
SCOTT BERTRAM L 0.01%  (26975) BDX / LOW /
Conroy Alexandre Senior Vice President 0.01%  (26436) BDX /
Mecklenburg Gary A 0.01%  (25453) BDX /
ORR JAMES F 0.01%  (24257) BDX /
ANDERSON BASIL 0.01%  (22596) BDX / HAS / MCO / SPLS /
DEGRAAN EDWARD 0.01%  (22416) BDX /
SHERMAN JEFFREY S Sr. VP and General Counsel 0.01%  (22094) BDX /
Fraser-Liggett Claire 0.01%  (21639) BDX /
Reidy Christopher R CFO and EVP of Administration 0.01%  (21397) BDX /
SOMMER ALFRED 0.01%  (20689) BDX / TROW /
LARSEN MARSHALL O 0.01%  (19733) AL / BDX / LOW / UTX /
OVERLOCK WILARD J JR 0.01%  (19442) BDX / EVR /
Mas Ribo Alberto EVP and Pres, Life Sciences 0.01%  (19126) BDX /
Lim James C Senior Vice President 0.01%  (18507) BDX /
Boles Donna M Senior VP - Human Resources 0.01%  (14607) BDX / CST /
Jones Christopher Ian Montague 0.01%  (14500) BDX /
MAHMOUD ADEL 0.01%  (13746) BDX / GNVC / INO /
Tharby Linda M Segment Pres. Life Sciences 0.01%  (13257) BDX /
Polen Thomas E Jr Segment President, Medical 0.01%  (12178) BDX /

Comments